- In the ADorable-1 study, 63% of patients achieved EASI-75 and 44% achieved IGA 0,1 at Week 16.
- 39% of patients reached EASI-90 and 35% had significant itch relief.
- EBGLYSS is an IL-13 inhibitor targeting atopic dermatitis.
- Topical corticosteroids were used alongside EBGLYSS in the trial.
Study Results
The Phase 3 ADorable-1 study demonstrated that 63% of pediatric patients with moderate-to-severe atopic dermatitis achieved EASI-75, indicating significant skin improvement, and 44% reached IGA 0,1, reflecting clear or almost clear skin by Week 16. Additionally, 39% of patients achieved EASI-90, a higher standard of near-complete skin clearance, and 35% experienced significant itch relief with a Pruritus NRS improvement of 4 points or more.
Safety and Tolerability
The safety and tolerability profile of EBGLYSS was consistent with previous studies in adults and adolescents, with no reported injection site pain.
Mechanism of Action
EBGLYSS is an interleukin-13 (IL-13) inhibitor that selectively blocks IL-13 signaling, which is a key cytokine in atopic dermatitis. This action helps to interrupt the type-2 inflammatory cycle in the skin, addressing issues such as skin barrier dysfunction, itch, skin thickening, and infection.
Trial Design
Participants in the ADorable-1 trial were randomized to receive either a placebo or a weight-based dose of EBGLYSS. Topical corticosteroids were administered starting two weeks before randomization and continued throughout the 16-week study. These could be reduced or stopped once patients achieved an IGA score of 2 or less. The co-primary endpoints were EASI-75 and IGA 0,1 at Week 16, with key secondary endpoints focusing on greater clinical improvement in disease severity and itch relief.
